Betmiga 50 mg
As listed in the register: Betmiga 50 mg, tabletten met verlengde afgifte
50 mg · tablet met verlengde afgifte
- Prescription only
- Urinary and reproductive system, hormones
- Active substance
- Mirabegron
- Made by
- Astellas Pharma Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Mirabegron). It describes the substance, not this exact product.
Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR.
Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 AR which increases bladder capacity.
Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis.
Effect of Food Mirabegron Monotherapy for Adult OAB There were no clinically significant differences in mirabegron pharmacokinetics when administered with or without food in adult patients.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-03
Safety of the active substance
From the US prescribing label for the same active substance (Mirabegron). It describes the substance, not this exact product.
- Mirabegron extended-release tablets are contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet [see Adverse Reactions ( 6.1, 6.2 )].
- Hypersensitivity to mirabegron or any inactive ingredients.
Most commonly reported adverse reactions with mirabegron monotherapy in adult patients with OAB (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection, and headache.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States9 matching products
European UnionNo exact match for this strength and form
Spain9 matching products
- BAXIRTO 50 mg · comprimido de liberación prolongada
- BETMIGA 50 MG · comprimido de liberación prolongada
- IRETIG 50 mg · comprimido de liberación prolongada
- MIRABEGRON ALTER 50 mg · comprimido de liberación prolongada
- MIRABEGRON CINFAMED 50 mg · comprimido de liberación prolongada
- MIRABEGRON NORMON 50 mg · comprimido de liberación prolongada
- MIRABEGRON STADA 50 MG · comprimido de liberación prolongada
- MIRABEGRON TEVA 50 mg · comprimido de liberación prolongada
Canada4 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Astellas Pharma Europe B.V. |
|---|---|
| Active substance | Mirabegron |
| Used in | Urinary and reproductive system, hormones |
| Strength | 50 mg |
| Form | tablet met verlengde afgifte |
| Classification | G04BD12 · Urinary and reproductive system, hormones |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Betmiga 50 mg, tabletten met verlengde afgifte |
| RVG | EU/1/12/809 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.